

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Susumu MUTO et al. Group Art Unit: 1645
Appl. No.: 10/516,292 Examiner: LANDAU, SHARMILA GOLLAMUDI
I.A. Filed : June 5, 2003 Confirmation No.: 5595

For: MEDICAMENT FOR TREATMENT OF CANCER

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56 and §§ 1.97 – 1.98, Applicant(s) wish to bring the following information to the attention of the Examiner.

Applicant(s) wish to make of record the documents listed on the attached form PTO-1449. Copies of the listed documents are attached, where required, as are noted English translations, or partial translations of pertinent portions, and/or English language abstracts, of any non-English language references. Statements of relevancy, where applicable, are also noted.

COMMONLY ASSIGNED

Document 5 is certain of Applicant's commonly assigned pending application(s), published application(s) or issued patent(s). In accordance with 37 CFR §1.98(a)(2)(ii), copies of the cited U.S. pending applications, published applications and/or issued patents, are not provided.

STATEMENT OF RELEVANCY

Documents * * have been cited in an International Search Report and/or Written Opinion, which indicates the relevancy thereof to the claims of the International Application. Copies of documents cited in the International Search Report should have been forwarded by the International Bureau and thus have not been provided.

Documents A and 2-4 have been cited in a Canadian Office Action dated November 2, 2009 (Document 1) that issued with respect to patent family member Canadian Patent Application No. 2,488,363, which indicates the relevancy of the cited documents. Any

necessary copy of these documents is being submitted herewith.

- Documents * * are cited in the Specification of the present application. Any necessary copy of these documents is being submitted herewith.
- Documents * * have been cited in the parent application(s) either by the Applicant(s) or by the examiner. Copies of these documents should be available in the parent application(s) and thus have not been provided herewith.
- Documents * * are related as patent family members.

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. This certification does not apply to any document previously cited in the present application.

FEES

- A payment in the amount required under 37 CFR §1.17(p) is provided herewith.

DEPOSIT ACCOUNT

- In the event that any additional fees are due with respect to this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 19-0089 of the undersigned

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Susumu MUTO et al.



Bruce H. Bernstein
Reg. No. 29,027

February 14, 2010
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

WALTER SCHIAPKOHL
REG. NO. 64,416